Menu
Search
|

Menu

Close
X

Champions Oncology Inc CSBR.OQ (NASDAQ Stock Exchange Capital Market)

6.10 USD
-- (--)
As of Jul 13
chart
Previous Close 6.10
Open --
Volume --
3m Avg Volume 6,501
Today’s High --
Today’s Low --
52 Week High 7.60
52 Week Low 2.44
Shares Outstanding (mil) 11.00
Market Capitalization (mil) 67.11
Forward P/E 16.78
Dividend (Yield %) -- ( -- )

LATEST NEWS

ADVERTISEMENT

RECOMMENDATION

Sell Hold Buy
1.50 Mean rating from 2 analysts

KEY STATS

Revenue (mm, USD)
FY18
15
FY17
15
FY16
11
FY15
9
EPS (USD)
FY18
0.560
FY17
-0.630
FY16
-1.201
FY15
-2.251
*Note: Units in Millions of U.S. Dollars
**Note: Units in U.S. Dollars

KEY RATIOS

Price to Earnings (TTM)
vs sector
16.78
33.20
Price to Sales (TTM)
vs sector
3.52
8.07
Price to Book (MRQ)
vs sector
142.26
4.28
Price to Cash Flow (TTM)
vs sector
16.53
22.38
Total Debt to Equity (MRQ)
vs sector
10.38
17.39
LT Debt to Equity (MRQ)
vs sector
4.87
13.21
Return on Investment (TTM)
vs sector
233.83
13.23
Return on Equity (TTM)
vs sector
297.13
15.28

EXECUTIVE LEADERSHIP

Joel Ackerman
Chairman of the Board, Since 2017
Salary: $11,620.00
Bonus: --
Ronnie Morris
President, Chief Executive Officer, Director, Since 2017
Salary: $15,061.00
Bonus: --
David Miller
Vice President - Finance, Since 2013
Salary: $215,000.00
Bonus: $6,885.00
Philip Breitfeld
Chief Strategic and Innovation Officer, Director, Since 2016
Salary: --
Bonus: --
David Sidransky
Lead Independent Director, Since 2017
Salary: --
Bonus: --

COMPANY PROFILE

Sector: Healthcare
Industry: Biotechnology & Medical Research
Address:

855 N Wolfe St Ste 619
BALTIMORE   MD   21205-1511

Phone: +1410.3690365

Champions Oncology, Inc. is engaged in the development and sale of technology solutions and products to personalize the development and use of oncology drugs. The Company has two business segments: Personalized Oncology Solutions (POS) and Translational Oncology Solutions (TOS). The POS segment provides physicians and patients information to help guide the development of personalized treatment plans. The TOS segment provides services to pharmaceutical and biotechnology companies seeking personalized approaches to drug development. Its TumorGraft Technology Platform consists of processes, physical tumors and information that it uses to personalize the development and use of oncology drugs. Each tumor from patients that it has preserved for implantation in mice, along with the patient data and molecular information associated with the tumors, are known as TumorGrafts or Patient Derived XenoGrafts of PDX Models. The collection of TumorGrafts is referred to as the Company's TumorBank.

SPONSORED STORIES